 |
0 Diseases |  |
0 Trials |
|
0 Trials |  |
3 News |  |
- Octagam (intravenous normal human immunoglobulin) / Octapharma, Kiovig (human normal immunoglobulin 10%) / Takeda
In vitro comparison between different 10% intravenous immunoglobulin preparations () - Oct 7, 2021 - Abstract #DGHO2021DGHO_1143;
Although different IVIg preparations essentially consist of polyclonal IgG, the different purification processes lead to variations in other characteristics. The IqYmune manufacturing process developed with a QbD approach has generated a 10% IVIg having a higher level of quality and enhanced safety profile while maintaining a high level of efficacy.
- || Iqymune (human immune globulin intravenous 10%) / LFB SA, Clairyg (intravenous normal human immunoglobulin) / LFB SA
Clinical, Journal: An international multicenter efficacy and safety study of IQYMUNE® in initial and maintenance treatment of patients with chronic inflammatory demyelinating polyradiculoneuropathy: PRISM study. (Pubmed Central) - Sep 29, 2021
The IqYmune manufacturing process developed with a QbD approach has generated a 10% IVIg having a higher level of quality and enhanced safety profile while maintaining a high level of efficacy. These results demonstrate that IqYmune® is an effective and well-tolerated treatment in patients with CIDP.
- || Iqymune (human immune globulin intravenous 10%) / LFB Biotechnologies, Clairyg (intravenous normal human immunoglobulin) / LFB Biotechnologies, Kiovig (human normal immunoglobulin 10%) / Takeda
Clinical, Journal, Head-to-Head: IqYmune® is an effective maintenance treatment for multifocal motor neuropathy: a randomised, double-blind, multicenter cross-over non-inferiority study versus Kiovig® - The LIME Study. (Pubmed Central) - Jun 8, 2020
No thromboembolic events nor hemolysis nor renal impairment were observed. In this first clinical trial comparing two IVIg brands for maintenance treatment of MMN, efficacy and tolerability of both brands were similar.
- |||||||||| aspirin / Generic mfg.
New P3 trial: Kawasaki Disease Coronary Artery Aneurysm Prevention trial (EUDRACT) - Feb 11, 2020
P3, N=262, , Sponsor: MRC CTU at UCL
- | Iqymune (human immune globulin intravenous 10%) / LFB SA, Clairyg (intravenous normal human immunoglobulin) / LFB SA
Enrollment change: A multinational study with I10E (Human Immunoglobulin) to demonstrate the efficacy and the safety of the product in patients suffering from deficiency in their immune system A primer immundeficiencia olyan (EUDRACT) - Apr 14, 2014
P2/3, N=60, Completed, Sponsor: LFB BIOTECHNOLOGIES
In this first clinical trial comparing two IVIg brands for maintenance treatment of MMN, efficacy and tolerability of both brands were similar. N=20 --> 60
- | Iqymune (human immune globulin intravenous 10%) / LFB SA, Clairyg (intravenous normal human immunoglobulin) / LFB SA
Trial completion: A multinational study with I10E (Human Immunoglobulin) to demonstrate the efficacy and the safety of the product in patients suffering from deficiency in their immune system A primer immundeficiencia olyan (EUDRACT) - Apr 14, 2014
P2/3, N=60, Completed, Sponsor: LFB BIOTECHNOLOGIES
N=20 --> 60 Ongoing --> Completed
- Iqymune (human immune globulin intravenous 10%) / LFB SA, Clairyg (intravenous normal human immunoglobulin) / LFB SA
New P3 trial: An open-label, multicentre efficacy and safety study of a human immunoglobulin (project code I10E) in patients with primary Immune ThrombocytoPenia (ITP) (EUDRACT) - Oct 5, 2011
P3, N=10, Ongoing, Sponsor: LFB BIOTECHNOLOGIES